NAVB

Navidea Biopharmaceuticals, Inc.

0.08 USD
+0.08 (+80,400.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Navidea Biopharmaceuticals, Inc. stock is up 101.25% since 30 days ago. The next earnings date is Jun 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.77% of the previous 25 May’s closed higher than April.

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability.